FDA Warning Letter Calls Attention to Celltrion's 'Poor' Aseptic Practices
Executive Summary
FDA warning letter to South Korean manufacturer Celltrion cites an extensive list of problems related to inadequate contamination controls and shows how companies launching biosimilars can be tripped up by GMP compliance problems.
You may also be interested in...
Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J
The latest drug development news and highlights from our US FDA Performance Tracker.
Celltrion’s Biosimilar Rituximab Brings Indication Carve Outs To US FDA Panel Review
Carve outs highlight growing problem for industry and FDA – the absence of an expedited process for adding or removing biosimilar indications; Celltrion seeks approval for only three of eight indications on label of reference product, Genentech’s Rituxan, due to intellectual property and exclusivity issues.
Celltrion’s Biosimilar Rituximab Brings Indication Carve Outs To US FDA Panel Review
Carve outs highlight growing problem for industry and FDA – the absence of an expedited process for adding or removing biosimilar indications; Celltrion seeks approval for only three of eight indications on label of reference product, Genentech’s Rituxan, due to intellectual property and exclusivity issues.